Prostate cancer is the most frequent epithelial neoplasia after skin cancer in men starting from 50 years and prostate-specific antigen (PSA) dosage can be used as an early screening tool. Prostate cancer imaging includes several radiological modalities, ranging from ultrasonography, computed tomography (CT), and magnetic resonance to nuclear medicine hybrid techniques such as single-photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. Innovation in radiopharmaceutical compounds has introduced specific tracers with di- agnostic and therapeutic indications, opening the horizons to targeted and very effective clinical care for patients with prostate cancer. The aim of the present review is to illustrate the current knowledge and future perspectives of nuclear medicine, including stand-alone diagnostic techniques and theragnostic approaches, in the clinical management of patients with prostate cancer from initial staging to advanced disease.

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives / Volpe, Fabio; Nappi, Carmela; Piscopo, Leandra; Zampella, Emilia; Mainolfi, Ciro Gabriele; Ponsiglione, Andrea; Imbriaco, Massimo; Cuocolo, Alberto; Klain, Michele. - In: CANCERS. - ISSN 2072-6694. - 15:19(2023), p. 4746. [10.3390/cancers15194746]

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives

Volpe, Fabio;Nappi, Carmela;Piscopo, Leandra;Zampella, Emilia;Mainolfi, Ciro Gabriele;Ponsiglione, Andrea;Imbriaco, Massimo;Cuocolo, Alberto;Klain, Michele
2023

Abstract

Prostate cancer is the most frequent epithelial neoplasia after skin cancer in men starting from 50 years and prostate-specific antigen (PSA) dosage can be used as an early screening tool. Prostate cancer imaging includes several radiological modalities, ranging from ultrasonography, computed tomography (CT), and magnetic resonance to nuclear medicine hybrid techniques such as single-photon emission computed tomography (SPECT)/CT and positron emission tomography (PET)/CT. Innovation in radiopharmaceutical compounds has introduced specific tracers with di- agnostic and therapeutic indications, opening the horizons to targeted and very effective clinical care for patients with prostate cancer. The aim of the present review is to illustrate the current knowledge and future perspectives of nuclear medicine, including stand-alone diagnostic techniques and theragnostic approaches, in the clinical management of patients with prostate cancer from initial staging to advanced disease.
2023
Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives / Volpe, Fabio; Nappi, Carmela; Piscopo, Leandra; Zampella, Emilia; Mainolfi, Ciro Gabriele; Ponsiglione, Andrea; Imbriaco, Massimo; Cuocolo, Alberto; Klain, Michele. - In: CANCERS. - ISSN 2072-6694. - 15:19(2023), p. 4746. [10.3390/cancers15194746]
File in questo prodotto:
File Dimensione Formato  
cancers-15-04746.pdf

accesso aperto

Descrizione: Articolo in rivista
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.07 MB
Formato Adobe PDF
2.07 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/940193
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact